Darrell Irvine

Darrell Irvine has been involved in a number of companies since 2002, when they began their career as a Professor at MIT. In 2012, they became Co-Founder and SAB member of Elicio Therapeutics, followed by Co-Founder and SAB member of Torque Therapeutics in 2015. In 2016, they became an SAB Member of Medicine by Design at the University of Toronto. Also in 2015, they became an SAB Member of SQZ Biotechnologies. In 2018, they became Co-Founder and SAB Member of Strand Therapeutics, followed by SAB Member of Mass General Cancer Center in 2019. In 2020, they became Co-Founder and SAB Member of Ankyra Therapeutics and SAB Member of Repertoire Immune Medicines. Most recently, in 2021, they became an SAB Member of Alloy Therapeutics, Inc.

Darrell Irvine earned their Doctor of Philosophy (PhD) in Polymer Science from the Massachusetts Institute of Technology between 1995 and 2000. Prior to that, they obtained a B. Phil. in Engineering Physics from the University of Pittsburgh between 1991 and 1995.